Tumor-specific T Cell Lines: Capacity to Proliferate and Produce Interleukin 2 in Response to Various Forms of Tumor Antigens
- 1 February 1992
- journal article
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 83 (2) , 184-193
- https://doi.org/10.1111/j.1349-7006.1992.tb00085.x
Abstract
Anti‐tumor proliferative T cell lines were established from cultures of lymph node cells from BALB/c mice immunized to syngeneic CSAIM fibrosarcoma with the CSAIM tumor cell membrane. The cultures were maintained throughout in the absence of exogenous interleukin 2 (IL2) J. Cell surface phenotypes of all T cell lines established were Thy‐1+, Ig‐, L3T4+ and Lyt‐2‐. Their proliferation was induced in a tumor antigen dose‐dependent fashion and a tumor antigen‐specific way. Such proliferative responses were inhibited by the addition to cultures of anti‐class II H‐2d (anti‐I‐Ad) or anti‐L3T4 but not of anti‐class I H‐2d or anti‐Lyt‐2 monoclonal antibody. None of the T cell lines exhibited any cytotoxic T lymphocyte activity but they all produced IL2 upon stimulation with CSAIM tumor antigens, indicating that they represent helper‐type T cell (Th) lines. The activation of these tumor‐specific Th lines was induced with either CSAIM tumor cells themselves, or their membrane or detergent‐solubilized fraction depending on the presence of antigen‐presenting cells (APC). Most importantly, activation was also inducible by membranous tumor antigen‐pulsed APC, which were capable of producing potent anti‐tumor protective immunity when administered in vivo into syngeneic BALB/c mice. These results indicate that the tumor‐specific Th lines established here can be activated with various forms of tumor antigens for their expression of helper function. Since Th lines of this type have not been described previously, our Th lines provide an intriguing tool for investigating the cellular and molecular mechanisms by which tumor‐specific Th recognize tumor antigens.Keywords
This publication has 29 references indexed in Scilit:
- Separation of the Tumor Rejection Antigen of Rous Sarcoma Virus-induced Murine FibrosarcomaJapanese Journal of Cancer Research, 1988
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- MONOCLONAL ANTIBODIES TO MOUSE MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGENSTransplantation, 1982
- Dissection of the proliferative and differentiative signals controlling murine cytotoxic T lymphocyte responses.The Journal of Experimental Medicine, 1982
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Murine syngeneic mixed lymphocyte response. I. Target antigens are self Ia moleculesThe Journal of Experimental Medicine, 1981
- Antigen-reactive T cell clones. I. Transcomplementing hybrid I-A-region gene products function effectively in antigen presentation.The Journal of Experimental Medicine, 1980
- Ir-genes in H-2 regulate generation of anti-viral cytotoxic T cells. Mapping to K or D and dominance of unresponsiveness.The Journal of Experimental Medicine, 1978
- Cell-mediated lympholysis of trinitrophenyl-modified autologous lymphocytes. Effector cell specificity to modified cell surface components controlled by H-2K and H-2D serological regions of the murine major histocompatibility complex.The Journal of Experimental Medicine, 1975
- FUNCTION OF MACROPHAGES IN ANTIGEN RECOGNITION BY GUINEA PIG T LYMPHOCYTESThe Journal of Experimental Medicine, 1973